Health News Releases

  • Today August 23
March 11, 2020 14:36
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide
Jesper Helmuth Larsen, CEO
March 09, 2020 11:34
AJ Vaccines To Develop Vaccine for COVID-19
“This endeavor reiterates our ambition to serve the global community, not only with existing effective high-quality vaccines, but also with the development of innovative new vaccines to answer the cur
March 06, 2020 17:11
Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced it
March 05, 2020 11:28
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclona
March 04, 2020 20:00
Takeda Completes Sale of Select OTC and Non-Core Assets to STADA
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG (“STADA”
March 04, 2020 13:19
Aragen Bioscience, Inc. and University of Technology, Sydney Enter Into MoU to Support and Accelerate Biologics R&D in Australia
Aragen Bioscience, Inc, a fully owned subsidiary of GVK BIO and a leading large molecule CRO, and University of Technology Sydney (UTS), the top-ranked young university in Australia, are pleased to an
March 03, 2020 16:29
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription ph
March 03, 2020 16:04
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion re
March 03, 2020 16:00
PDC*line Pharma Announces the Administration of a First Patient With Its Therapeutic Cancer Vaccine Candidate (PDC*lung01) Targeting Non-small Cell Lung Cancer
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative
March 03, 2020 15:21
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin Americ
March 02, 2020 13:44
Coronavirus IS a Pandemic — WHO, Declare It Now!
Since AIDS Healthcare Foundation (AHF) released a statement this past Tuesday calling for World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus to declare the novel coronavirus (CO
March 02, 2020 10:08
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketin
March 02, 2020 10:06
Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommend
February 28, 2020 10:25
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) pl
The Success of ReSound Technology Is Amplified and Multiplied for Even More People With Hearing Loss
February 27, 2020 17:34
The Success of ReSound Technology Is Amplified and Multiplied for Even More People With Hearing Loss
GN Hearing, the innovation leader in hearing aid technology, today launches a range of exciting new ReSound hearing aid solutions, a move which is in line with the company’s continuous strategic focus
February 27, 2020 11:40
Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that it has acquired PvP Biologics, Inc. following the conclusion of a Phase 1 proof-of-mechanism study of investigationa
February 26, 2020 11:49
Masimo and MS Westfalia GmbH (MSW) Expand Partnership to Add Masimo SedLine® Brain Function Monitoring, O3® Regional Oximetry, and Oxygen Reserve Index (ORi™) to the MSW Modular Point-of-Care Hybrid Jenny
Masimo (NASDAQ: MASI) and MS Westfalia GmbH (MSW) announced today that MSW will integrate additional Masimo measurement technologies into MSW’s plug-and-play hybrid Jenny platform, to help clinicians
February 25, 2020 16:45
Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s supplemental New Drug Applicati
February 25, 2020 14:37
Bioventus Recognizes 25 Years of Proven Bone Healing from EXOGEN
Bioventus, a global leader in orthobiologic solutions, is recognizing 25 years of proven bone healing with its EXOGEN Ultrasound Bone Healing System. EXOGEN uses low-intensity pulsed ultrasound (LIPUS
February 25, 2020 13:29
Arima Genomics Completes Series A Financing
Arima Genomics, Inc., a company focused on research tools to accelerate the understanding of genome sequence and structure toward their role in human health and disease, announces that it has complete
February 25, 2020 13:07
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary
February 20, 2020 17:50
Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis
Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from m
February 20, 2020 10:55
Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH
Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, today announced the
February 19, 2020 10:26
Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox
Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow (www.mystudywindow.com), a digital platform empowering patients, families, caregivers, and doctors to
February 17, 2020 13:35
Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutan
25 per page50 per page75 per page100 per page